MENINGITIS RESEARCH FOUNDATION

Their core work

Meningitis Research Foundation is a UK-based disease-focused charity and research body dedicated to eliminating meningitis and septicaemia through research, education, and public health advocacy. In EU research, they contribute as a specialist patient and advocacy partner, bringing disease-specific clinical knowledge and community networks to vaccine policy and ethics consortia. Their H2020 work shows two distinct contributions: ensuring ethical and equitable design of vaccine trials (informed consent for vulnerable groups), and evaluating real-world influenza vaccine effectiveness through public-private collaboration frameworks. They serve as a credibility anchor in consortia that need patient voice, disease burden evidence, and public health policy expertise.

What they specialise in

How they've shifted over time

Both projects began in 2017, so the timeline is narrow, but a thematic shift between the two is visible. Their first project (I-CONSENT) centred on equity and ethics — gender, age, and protecting vulnerable populations in vaccine research design. Their second project (DRIVE) moved toward applied public health outcomes: measuring vaccine effectiveness, building governance structures, and managing public-private partnerships. This suggests a trajectory from upstream research ethics and patient advocacy toward downstream policy implementation and effectiveness monitoring — a natural maturation for a disease foundation gaining EU research experience.

Moving from an ethics and patient-voice role in research design toward active participation in vaccine policy evaluation and public-private governance — suggesting growing technical engagement beyond pure advocacy.

How they like to work

They have never coordinated an H2020 project, consistently joining as a participant. Despite only two projects, they engaged with 26 unique partners across 7 countries, indicating participation in large, multi-actor consortia typical of RIA and CSA health calls. This pattern strongly suggests they are brought in as a specialist contributor — for their disease authority, patient network, or ethics credibility — rather than for project management capacity.

Twenty-six unique partners across 7 countries from just two projects points to large, geographically diverse consortia — consistent with the EU-wide scope of vaccine policy and clinical ethics research. Their collaborative footprint is disproportionately broad relative to their project count, suggesting well-connected consortium membership.

What sets them apart

As a disease-dedicated patient advocacy foundation rather than a generic research institute, Meningitis Research Foundation brings something few academic or industry partners can replicate: direct credibility with patient communities, real-world disease burden knowledge, and trusted relationships with clinicians and public health bodies in the meningitis space. For consortium builders in vaccine policy, immunisation ethics, or communicable disease research, they offer the patient and civil society voice that strengthens both the science and the grant narrative. Their dual presence in ethics (I-CONSENT) and effectiveness research (DRIVE) shows they can contribute meaningfully across the research-to-policy pipeline.

Highlights from their portfolio

• DRIVE
  Largest budget award (EUR 150,615) and longest duration (to 2022), focused on building European-level methodological frameworks for real-world influenza vaccine effectiveness — directly relevant to vaccine surveillance and public health policy.
• I-CONSENT
  Addressed an underserved gap in clinical research governance by improving informed consent guidelines specifically for vulnerable populations through a gender and age lens — broadly applicable beyond vaccines to any interventional research.